MetaCap

Avantor Inc. (AVTR)

NYSE: AVTRIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD

14.84-0.28 (-1.85%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AVTR stock chart

Technical analysis

Key statistics

All statistics
Market cap
$10.06B
52-week range
7.27 – 17.45
Day range
14.80 – 15.50
Volume / Avg
12.25M / 8.77M
Beta
—

52-week range

$7.27$17.45

AVTR stock today

On Nov 20, AVTR ended the session at $14.84, shedding $0.28 (1.85%), versus the S&P 500's 3.70% decline. Shares are 15.0% below their 52-week high of $17.45, set on Oct 22, 2026 and 104.3% above the 52-week low of $7.27, in the middle of the past year's range. AVTR is up 29.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 28.8%.

Avantor trades at 29.7x its trailing twelve-month earnings per share of $0.50. Its forward P/E of 16.7x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Avantor

Company profile

Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips.

Industry
Biotechnology: Laboratory Analytical Instruments
CEO
Mr. Emmanuel Ligner
Headquarters
Radnor, PA
Employees
13,500
IPO year
2019

Financial highlights

Full financials

In fiscal 2025, Avantor generated $6.55 billion in revenue, down 3.4% from fiscal 2024, its first annual decline since 2024. Avantor reported a net loss of $530.2 million, compared with net income of $711.5 million a year earlier. Gross margin was 32.7% (down from 33.6%) and operating margin -3.8%.

Avantor annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2020
Revenue$6.55B$6.78B$6.97B$7.51B$7.39B
Growth-3.41%-2.64%-7.26%+1.71%+15.52%
Net income$-530.20M$711.50M$321.10M$686.50M$572.60M
EPS (diluted)$-0.78$1.04$0.47$1.01$0.85

Analyst forecast

Forecast

Consensus (15 analysts)

hold

Avg. price target

$17.35+16.91%

  • Strong buy 0
  • Buy 2
  • Hold 12
  • Sell 0
  • Strong sell 1

Target range

Low $16.00High $19.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 28, 2026
EPS actual vs est.
$0.30 vs $0.21
Surprise
+42.86%

AVTR news

All AVTR news

Avantor peers

Industrials sector
AVTR peer companies
CompanyPrice% ChgMarket capCompare
BIOBio-Rad Laboratories Inc. Class A358.90-2.34%$9.65Bvs AVTR
BRKRBruker Corporation56.46-9.08%$8.62Bvs AVTR
TXG10x Genomics Inc. Class A51.80-9.72%$6.81Bvs AVTR
RVTYRevvity Inc.145.22-4.20%$16.21Bvs AVTR
ALMRAlamar Biosciences Inc.26.48-7.67%$1.84Bvs AVTR
CTKBCytek Biosciences Inc.6.12-3.16%$800.40Mvs AVTR
PACBPacific Biosciences of California Inc.1.63-7.39%$508.95Mvs AVTR
NAUTNautilus Biotechnology Inc.2.12-2.30%$270.03Mvs AVTR

Indexes, lists and sector

Avantor stock FAQ

What is Avantor's stock price today?

AVTR last traded at $14.84 as of Nov 20, 4:00 PM EST, down 1.85% on the day. Prices are delayed at least 15 minutes.

What is AVTR's P/E ratio?

AVTR trades at a trailing P/E ratio of 29.68 and a forward P/E of 16.73.

Who is Avantor's CEO?

Mr. Emmanuel Ligner is the chief executive officer of Avantor Inc., which has about 13,500 employees.

What is the AVTR 52-week high?

The 52-week high for AVTR is $17.45 and the 52-week low is $7.27. The stock is currently 15.0% below its high.

Compare AVTR